Completion of Acclaim-1 dose escalation: Recommended Phase 2 dose of quaratusugene ozeplasmid gene therapy and Osimertinib

被引：0
|
作者：
Spira, Alexander I.
Berz, David
Jotte, Robert M.
Pachipala, Krishna K.
Berger, Mark S.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-A065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A065
引用
收藏
页数：2
相关论文
共 50 条
  • [21] BELUMOSUDIL PHASE 1 DOSE-ESCALATION STUDY IN HEALTHY VOLUNTEERS AND PHASE 2 STUDY IN PATIENTS WITH CGVHD WHO FAILED ≥1 LINE OF SYSTEMIC THERAPY IN CHINA
    Wang, Ying
    Wu, Depei
    Zhang, Xiang
    Li, Yuhua
    He, Yanjie
    Liu, Qifa
    Xuan, Li
    Li, Zhenyu
    Qi, Kunming
    Sun, Yuqian
    Wang, Shunqing
    Mo, Wenjian
    Gao, Lei
    Hua, Ye
    Wang, Yu
    Zhang, Ying
    Fu, Nico
    BONE MARROW TRANSPLANTATION, 2024, 59 : 308 - 309
  • [22] Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
    Maguire, Albert M.
    High, Katherine A.
    Auricchio, Alberta
    Wright, J. Fraser
    Pierce, Eric A.
    Testa, Francesco
    Mingozzi, Federico
    Bennicelli, Jeannette L.
    Ying, Gui-shuang
    Rossi, Settimio
    Fulton, Ann
    Marshall, Kathleen A.
    Banfi, Sandra
    Chung, Daniel C.
    Morgan, Jessica I. W.
    Hauck, Bernd
    Zelenaia, Olga
    Zhu, Xiaosong
    Raffini, Leslie
    Coppieters, Frauke
    De Baere, Elfride
    Shindler, Kenneth S.
    Volpe, Nicholas J.
    Surace, Enrico M.
    Acerra, Carmela
    Lyubarsky, Arkady
    Redmond, T. Michael
    Stone, Edwin
    Sun, Junwei
    McDonnell, Jennifer Wellman
    Leroy, Bart P.
    Simonelli, Francesca
    Bennett, Jean
    LANCET, 2009, 374 (9701): : 1597 - 1605
  • [23] A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma
    Klatzmann, D
    Cherin, P
    Bensimon, G
    Boyer, O
    Coutellier, A
    Charlotte, F
    Boccaccio, C
    Salzmann, JL
    Herson, S
    HUMAN GENE THERAPY, 1998, 9 (17) : 2585 - 2594
  • [24] Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer
    Jo, J-C
    Lee, J-L
    Ryu, M-H
    Chang, H. M.
    Kim, M.
    Lee, H. J.
    Kim, H-S
    Shin, J-G
    Kim, T-W
    Kang, Y-K
    BRITISH JOURNAL OF CANCER, 2012, 106 (10) : 1591 - 1597
  • [25] Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer
    J-C Jo
    J-L Lee
    M-H Ryu
    H M Chang
    M Kim
    H J Lee
    H-S Kim
    J-G Shin
    T-W Kim
    Y-K Kang
    British Journal of Cancer, 2012, 106 : 1591 - 1597
  • [26] Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials
    Nicolas Penel
    Alain Duhamel
    Antoine Adenis
    Patrick Devos
    Nicolas Isambert
    Stéphanie Clisant
    Jacques Bonneterre
    Investigational New Drugs, 2012, 30 : 653 - 661
  • [27] Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials
    Penel, Nicolas
    Duhamel, Alain
    Adenis, Antoine
    Devos, Patrick
    Isambert, Nicolas
    Clisant, Stephanie
    Bonneterre, Jacques
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 653 - 661
  • [28] PHASE 1-2 DOSE-ESCALATION STUDY OF VB-111, AN ANTI-ANGIOGENIC GENE THERAPY, AS MONOTHERAPY AND IN COMBINATION WITH BEVACIZUMAB, IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Brenner, Andrew
    Cohen, Yael
    Vredenburgh, James
    Peters, Katherine
    Blumenthal, Deborah
    Bokstein, Felix
    Breitbart, Eyal
    Bangio, Livnat
    Sher, Naamit
    Harats, Dror
    Wen, Patrick
    NEURO-ONCOLOGY, 2014, 16
  • [29] Hepatocyte Growth Factor Gene Therapy for Patients With Critical Limb Ischemia: Results of a Phase I Dose-Escalation Trial
    Henry, Timothy D.
    Goldman, JoAnne
    Wang, Yale L.
    Lips, Daniel L.
    Dulas, Daniel
    McMillan, William D.
    Duval, Sue
    Biggs, Thomas A.
    Hirsch, Alan T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (10) : A40 - A40
  • [30] Results of a phase 1 open-label, dose escalation study of gene therapy with AAV2-hAQP1 as treatment for radiation-induced xerostomia and parotid gland hypofunction
    Brennan, M.
    Passineau, M.
    Saunders, D.
    Sroussi, H.
    Gaudilliere, D.
    Pfister, D.
    Fernandez, A.
    Liu, J.
    Dubois, N.
    Zeldin, R.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A48 - A48
12345